Collateral Damage from Illumina (ILMN) Warning: Looking For New Buys
11/21/11 The diagnostics and tools sector remain weak trading down about 1.9% slightly better than NASDAQ down 2.5%. Within the life sciences we prefer biopharmaceutical stocks because of M&A potential and less sensitivity to earnings. From October 11,2011 Despite a nice rally yesterday we...
Investor Uprising – Guide to Biotech Investing
There is an excellent Guide to Biotech Investing on the Investor Uprising blog. You will need a IU account to view the document http://www.investoruprising.com/document.asp?doc_id=206689...
Innovations Continue to Drive Market Gains
Over $50B in Product Sales Have Been Posted in the Last 20 Years as a Result of Biotech Advances Biotechnology stocks were up about 12% over the past 12 months through February 2011, underperforming the Nasdaq, which was up 29%. The NYSE Arca Biotech ETF did better, up 23%. Since the recent...
Life Science Stocks Rally into the Third Day Up Over 2%
Risk is on for Life Science Stocks The rally that began late tuesday continued into the third day with major biotech indices up over 2%.The Rayno Life Science Portfolio was up 2.2% with recent reiterated buys up even more: AMRI, EXAS, GPRO, OPTR, REGN, SGEN, and VPHM. Illumina (ILMN $39.93)...
Another Wild Day: Market Roars Back in Final 40 Minutes
Market Turns Up at 3:18 EDT for 2.28% Gain in S&P: 1080 is the mark for a 2011 bottom After a roller coaster day where stocks were ready to break the scary 1080 level on the S&P, it abruptly reversed course for a 4.1% gain from the bottom. As usual the headline (or shall we say quote)...
